OPN5 and B-cell chronic lymphocytic leukemia: Overall, these data demonstrate OPN5 treatment lessens T-cell immune dysfunction in the splenic microenvironment, reinforcing that BET protein inhibition repairs the suppressive microenvironment in CLL.